酒鬼酒(000799.SZ)逼近漲停 股價再創新高 市值超630億元
格隆匯1月7日丨酒鬼酒(000799.SZ)延續強勢上漲行情,午間收漲9.58%,高見195.97再創新高價,暫成交18.79億元,總市值633.6億元。從2020年年初至今,一年時間,酒鬼酒漲幅已超400%。春節將至,白酒表現出了更強的剛需性,同時在消費升級的帶動下,白酒行業長期成長空間較大。酒鬼酒擁有“內參”、“酒鬼”、“湘泉”三大系列產品,日前旗下52度500ml內參酒價格上調。2020年在疫情的艱難環境中,公司憑藉內參挺過難關、實現靚麗增長,中信證券預計2020年收入同增15%左右,內參是公司核心驅動力。另外,酒鬼酒入選了格隆匯2021年“下注中國”十大核心潛力資產。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.